Entinostat (MS-275)

Catalog No.S1053 Synonyms: SNDX-275

Entinostat (MS-275) Chemical Structure

Molecular Weight(MW): 376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

Size Price Stock Quantity  
In DMSO USD 91 In stock
USD 70 In stock
USD 150 In stock
USD 270 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 61 Publications

14 Customer Reviews

  • (A) U87 cells were cultured in the presence of DMSO, 1 uM MS-275 alone, 100 ng/ml IFN-λ1 alone, or both for the course of 4 d. Cell numbers were manually determined by hemacytometer counting at the indicated time points. (B, F) Cell proliferation of U87 cells or U87 spheroids in 3D culture with indicated treatment were performed using the WST-1 assay, which measures active cellular metabolism. (C) U87 spheroid formation in 3D culture was photographed at day 14 in culture (representative images are shown; 200x magnification). (D-E) Quantification of the relative sizes and numbers of U87 spheroids in (C). (G) Cell cycle analysis was performed in U87 cells with indicated treatment using propidium iodide staining. Numbers in the histogram show fractions (percent) of sub-G1, N, 2N, and polyploidy from left to right. (H) U87 cells with indicated treatment were stained with Annexin V-FITC and 7-AAD. Numbers indicate the percentage of FITC-positive cells (upper left quadrant). FITC, fluorescein isothiocyanate; 7-AAD, 7-Aminoactinomycin. In all panels, data represent the mean and SEM of at least three experiments.

    PLoS Biol 2014 12, e1001758. Entinostat (MS-275) purchased from Selleck.

    Numerous APC (+) oligodendrocytes (middle upper panel) with ellipsoid nuclei labeled with Sytox (left upper panel) were observed in 8 week old Thy-1 mitoCFP control MONs. NF-200 (+) neurofilaments extended along the MON as linear individual fibers (right upper panel). A period of OGD (60 min) caused a significant loss of APC (+) oligodendrocytes, a gain in the appearance of pyknotic nuclei (dense, brighter nuclei, white arrows, OGD panel), and loss of NF-200 (+) axon structures, which were, replaced with axonal head and bulb formation (white asterisks). Pretreatment with SAHA (1uM) or MS-275 (1uM) effectively preserved APC (+) oligodendrocytes, together with numerous linear individual NF-200 (+) axons. Note fewer pyknotic nuclei (white arrows, SAHA and MS-275 panels) after OGD in MONs treated with SAHA or MS-275.

    J Neurosci 2011 31, 3990-9. Entinostat (MS-275) purchased from Selleck.

  • Inhibition of HDAC1-mediated DNMT1 deacetylation promotes DNMT1 proteasomal degradation. (A) Knockout of HAUSP potentiates HDAC inhibitor (HDACi)-induced DNMT1 degradation. Parental or HAUSP KO DLD1 cells were treated or not with 5 μM HDACi MS-275 for 72 hours and cell lysates were blotted with the indicated antibodies. (B) HDAC inhibition induces DNMT1 ubiquitination. HAUSP WT or KO cells were treated with or without HDACi for 24 hours and MG132 for 12 hours before being harvested to make cell lysates. DNMT1 immunoprecipitates were blotted with an antibody against ubiquitin. Because the abundance of DNMT1 in the HAUSP KO cells is lower than in WT cells, more KO cells were used than WT cells to obtain equal amounts of precipitated DNMT1 proteins. (C) DNMT1 is acetylated after HDACi treatment. DNMT1 immunoprecipitates from cells treated with HDACi were blotted with an antibody against acetylated lysine (Ac-K). (D) A DNMT1 acetylation site mutant is resistant to HDACi-induced degradation. HEK 293 cells were transfected with WT DNMT1 or a DNMT1 mutant lacking four known acetylation sites (K173R, K1113R, K115R, and K117R) and treated with MS-275 for 48 hours and with CHX for 24 hours. Cell lysates were blotted with the indicated antibodies. (E) Knockdown of HDAC1 decreases the abundance of DNMT1. RKO cells were treated with the indicated concentration of doxycycline (Dox) for 48 hours to induce expression of an shRNA directed against HDAC1. Western blots were performed with the indicated antibodies. (F) Knockdown of HDAC1 leads to increased acetylation of DNMT1. RKO cells expressing an inducible HDAC1 shRNA were treated with or without Dox (4 mg/ml) for 36 hours and then with MG132 for 12 hours. DNMT1 immunoprecipitates were blotted with an antibody against Ac-K. Cell lysates were also blotted with antibodies against HDAC1 and b-actin.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    The E3 ligase UHRF1 ubiquitinates DNMT1. (A) HDAC inhibition enhances DNMT1 interaction with UHRF1. HEK 293 cells were transfected with plasmids expressing Myc-DNMT1 and Flag-UHRF1 and treated with or without MS-275 for 24 hours. Myc-DNMT1 immunoprecipitates were blotted with the indicated antibodies. (B and C) HDAC inhibition enhances the interaction of endogenous DNMT1 and UHRF1. Cells were treated with or without MS-275 and UHRF1 (B) or DNMT1 (C) immunoprecipitates were blotted with the indicated antibodies. (D) UHRF1 ubiquitinates DNMT1. HEK 293 cells were transfected with the indicated plasmids. Antibodies against Myc immunoprecipitates were blotted with antibody against HA to detect ubiquitinated DNMT1. Myc-DNMT1D, DNMT1 mutant lacking the HAUSP-interacting domain. UHRF1DRING, UHRF1 with a RING domain deletion. (E) Knockdown of UHRF1 blocks HDACi-induced DNMT1 degradation. HEK 293 cells were transfected with control siRNA or siRNAs against UHRF1 and treated with or without MS-275. Western blotting was performed with the indicated antibodies. (F) Overexpression of UHRF1 leads to degradation of a DNMT1 mutant lacking the HAUSP-interacting domain (DNMT1D). Full-length DNMT1 or DNMT1D was cotransfected into HEK 293 cells with the indicated expression vectors. Cell lysates were blotted with the indicated antibodies. (G) DNMT1, HAUSP, UHRF1, HDAC1, and PCNA associate with Tip60. Flag-tagged Tip60 immunoprecipitates were blotted with the indicated antibodies.

     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

  • HAUSP KO cells are more sensitive to HDACi-induced apoptosis.(A) HDAC inhibition induces apoptosis in HAUSP KO cells.HAUSP WT or KO cells were treated with or without MS-275 at the indicated concentration for 72 hours, then fixed and stained with propidium iodide. Flow cytometric analyses were used to profile sub-G1, G1, and G2-M cell populations. Apoptotic cells were quantified after the indicated clones were treated with either 5 or 10 μM MS-275. The means and SDs of three independent experiments were plotted (*P<0.001, t test). (B) HDAC inhibition induces apoptosis in HAUSP KO cells but leads to G2-M arrest in WT cells.Cell cycle profiles of HAUSP WT or KOcells that were treated or not with 5 μM MS-275. (C)HDAC inhibition increases the abundance of apoptotic cell markers. The indicated cells were treated with or without MS-275 for 72 hours.Cell lysates were blotted with antibodies against cleaved caspase 3 and β-actin. (D) Ectopic overexpression of DNMT1 in HAUSP KO cells suppresses apoptosis. HAUSP KO clones or HAUSP KO cells inducibly

    overexpressingDNMT1 were treatedwith 10 μM MS-275. Apoptotic cell populations were quantified by fluorescence-activated cell sorting (FACS) analyses (*P < 0.001, t test). Cell lysates from these cells were blotted with the indicated antibodies. (E) HDAC inhibition arrests the growth of HAUSP KO cells. DLD1, HAUSP KO, and KO cells ectopically expressing HAUSP were treated with the indicated concentration of MS-275 for 4 days. Cell numbers were determined and data from eight replicates were plotted (**P <0.001, t test). (FandG) HDACi inhibits tumor xenograft formation ofHAUSP KOcells.Athymic nudemice (five in each group)were injectedsubcutaneously and bilaterallywith cells of the indicated genotypes. Mice were treated with or without MS-275 at 15mg/kg for 4 weeks. Tumors were harvested and photographed (F). Tumor sizes of the indicated groupsweremeasuredweekly and theaveragevolumes at each timepoint were plotted (G).MANOVA analyses were performed to determine whether there was an overall difference of the tumor sizes, as well as whether there was a difference in development over time of tumor sizes between the two groups (P < 0.0001).
     

     

    Sci Signal 2010 3, ra80. Entinostat (MS-275) purchased from Selleck.

    Notch1ICD, Notch2ICD, and Notch3ICD were transduced into human aortic SMCs, which were then treated with HDAC inhibitors TSA or MS-275 or with vehicle DMSO (con). The top 2 rows are different exposures of the same blot to detect the epitope tags on the N ICD constructs. Longer (top row) and shorter ( second row) exposures are shown because t he level of N2ICD expression was lower than that of N1ICD and N3ICD. SMC markers were analyzed and were similarly induced by activation of each Notch r eceptor. Both TSA and MS-275 significantly suppressed the induction of SMC proteins by Notch activation.

    J Am Heart Assoc 2012 1, e000901. Entinostat (MS-275) purchased from Selleck.

  • LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Entinostat (MS-275) purchased from Selleck.

    Inhibition of LSD1 activity by HDAC inhibitors. a MDA-MB-231 and MDA-MB-468 cells were exposed to indicated HDAC inhibitors for 24 h.

     

     

    Exp Dermatol 2010 19, 1096-1102. Entinostat (MS-275) purchased from Selleck.

  • Histone acetylation in the spinal cord after HDACI treatment. Histone acetylation in the lumbar spinal cord of mice receiving i.t. SAHA (25 μg) or MS-275 (0.5 μg) for 30 min was analyzed by immunoblot (A, B) and immunofluorescent histochemistry (C) for antigens indicated. Animals receiving i.t. saline were used as control. Images of the H3K9/18ac signals in the left half of the lumbar spinal cord are shown in the first row in C. Immunosignals of indicated antigens in the superficial dorsal horn are presented in the rest rows in C.

    Mol Pain 2010 6, 51. Entinostat (MS-275) purchased from Selleck.

    B. Confluent quiescent foreskin fibroblasts were treated with HDAC1 inhibitor or vehicle for 24 hours. Type I procollagen protein levels in whole cell lysates were determined by immunoblotting. A representative result of three independent experiments is shown. The band density was evaluated by densitometry. C. Under the same conditions, mRNA levels of the α1(I) collagen (COL1A1) gene were determined using reverse transcription quantitative real-time PCR. The graph represents -fold change in COL1A1 mRNA levels in comparison to unstimulated controls, which were arbitrarily set at 100. The mean and SD from three separate experiments are shown. * p<0.05 versus control cells treated with vehicle.

    PLoS One 2013 8, e74930. Entinostat (MS-275) purchased from Selleck.

  •  

    HDAC inhibition increases SMN-luciferase reporter mRNA levels. qRT-PCR was used to measure increases of SMN-luciferase mRNA following treatment with HDAC inhibitors. Fold increase of mRNA was normalized to GAPDH.

    Biochem Bioph Res Co 2010 414, 25-30. Entinostat (MS-275) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Entinostat (MS-275) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM MS-275 was added.

     

     

    2011 Dr. Zhang of Tianjin Medical University. Entinostat (MS-275) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Targets
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
In vitro

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 M1;sXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NECwNVRKSzVyPUCuNFYyKM7:TR?= MVPTRW5ITVJ?
ALL-PO NGjJVnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XwSWlEPTB;MD6wOlM2PSEQvF2= NFTSXW1USU6JRWK=
697 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33Gd2lEPTB;MD6wPVk4PiEQvF2= NFvI[5RUSU6JRWK=
NCI-H748 MorRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TjcWlEPTB;MD6xNFM{PCEQvF2= NVm1Z41nW0GQR1XS
NKM-1 NYnsTIdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwMUC5NVIh|ryP MV\TRW5ITVJ?
ES1 M4\VbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULaUId3UUN3ME2wMlEyOjV3IN88US=> NHnsWFdUSU6JRWK=
NCI-H1963 NVK3WnFUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnLTYpKSzVyPUCuNVE2PzlizszN NH3IdGxUSU6JRWK=
NCI-H1417 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;zeWlEPTB;MD6xNlk4PCEQvF2= NHnNOGpUSU6JRWK=
NEC8 M1e2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DMPGlEPTB;MD6xN|UzPyEQvF2= NFH1eW1USU6JRWK=
CRO-AP2 MonXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLIZWN{UUN3ME2wMlE3QDh7IN88US=> MlvyV2FPT0WU
A3-KAW NVjPNWxrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknOTWM2OD1yLkG3OlI4KM7:TR?= MonnV2FPT0WU
SF539 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvGTWM2OD1yLkG5OVk{KM7:TR?= Ml3IV2FPT0WU
NOS-1 M4jzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni1TWM2OD1yLkG5OlE6KM7:TR?= NE\xcHhUSU6JRWK=
NTERA-S-cl-D1 NVjPeYhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMkCxNVMh|ryP NUPo[lFoW0GQR1XS
COR-L88 MkLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlWwTWM2OD1yLkKyPVU6KM7:TR?= NVqzN2ZtW0GQR1XS
EM-2 Mn3yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTKTWM2OD1yLkK0NFc6KM7:TR?= NV\TeWJMW0GQR1XS
KARPAS-45 NYe2fZNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fBd2lEPTB;MD6yO|g{OyEQvF2= MoC2V2FPT0WU
DSH1 NV3YfphsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljiTWM2OD1yLkK4O|A5KM7:TR?= M{PWcXNCVkeHUh?=
HT-144 NWfwT5JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwM{CyOVYh|ryP MoP6V2FPT0WU
ATN-1 MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\mVlVKSzVyPUCuN|A2PzZizszN MoTqV2FPT0WU
HEL MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C4OGlEPTB;MD6zNVM1QCEQvF2= M3XP[nNCVkeHUh?=
NB12 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwM{G3OVYh|ryP M3\SS3NCVkeHUh?=
LU-139 M2TldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\ETWlEPTB;MD6zN|UyKM7:TR?= MlHUV2FPT0WU
J-RT3-T3-5 MnOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPWRZlLUUN3ME2wMlM{PzF4IN88US=> MoWzV2FPT0WU
MOLT-13 M3Xjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;xfVNKSzVyPUCuN|M5OSEQvF2= NVHnXFJrW0GQR1XS
SR NWLFS5o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn2zTWM2OD1yLkO0NlYyKM7:TR?= MoDRV2FPT0WU
CMK MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W5PGlEPTB;MD6zOVczPyEQvF2= NX[5ZYNoW0GQR1XS
ES8 NYPiN3pwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGSyN4dKSzVyPUCuN|YxOjJizszN MVHTRW5ITVJ?
LB647-SCLC MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;NfHBwUUN3ME2wMlM3PzNizszN MVLTRW5ITVJ?
TE-8 Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4KzOGlEPTB;MD6zOlk{PSEQvF2= M{HybnNCVkeHUh?=
BV-173 NEjxe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwM{exNlEh|ryP MWfTRW5ITVJ?
DEL MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\zVGlEPTB;MD6zO|Q5PyEQvF2= MkHWV2FPT0WU
ARH-77 NHrzfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHrNYNJUUN3ME2wMlM5OTl|IN88US=> NXPzRopIW0GQR1XS
NCCIT Mn:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknUTWM2OD1yLkO4OlQ6KM7:TR?= NHnWRZhUSU6JRWK=
RPMI-8402 NYLEUmM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfzXWR5UUN3ME2wMlM5PzBzIN88US=> Mni2V2FPT0WU
MONO-MAC-6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwM{i3O|Yh|ryP M321fHNCVkeHUh?=
SK-MM-2 M2HhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHwTWM2OD1yLkO5PFY5KM7:TR?= NFS4UZlUSU6JRWK=
CHP-126 Mn7DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3RVXlKSzVyPUCuOFAzOzFizszN NFfPR29USU6JRWK=
A101D NHKyU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTBwNECzJO69VQ>? NYi5eIhsW0GQR1XS
SCH NInieZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwNECzOFIh|ryP NF;QfmlUSU6JRWK=
NMC-G1 NG\3TVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XEVWlEPTB;MD60NFM3PyEQvF2= NFuwUZdUSU6JRWK=
NCI-H209 M{jafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTOTWM2OD1yLkSwOlE{KM7:TR?= MmGxV2FPT0WU
MOLT-16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXNTWM2OD1yLkSxNFE4KM7:TR?= MVnTRW5ITVJ?
RPMI-6666 M13Ic2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3voRmlEPTB;MD60NVEzKM7:TR?= NXvRe4FPW0GQR1XS
OPM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYja[HdzUUN3ME2wMlQyPTF|IN88US=> NETnVFRUSU6JRWK=
MRK-nu-1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;V[XF7UUN3ME2wMlQ{OTV|IN88US=> M1vKeXNCVkeHUh?=
BC-1 MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC2R|lKSzVyPUCuOFM1ODNizszN M2HWSXNCVkeHUh?=
MHH-NB-11 NYDpTGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\TXWtlUUN3ME2wMlQ{PDV|IN88US=> M3\uRnNCVkeHUh?=
Ramos-2G6-4C10 NGnrPGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvt[WoyUUN3ME2wMlQ{QDl5IN88US=> NGSwe4JUSU6JRWK=
LS-513 M1v3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPtTWM2OD1yLkS0OVAyKM7:TR?= Moe0V2FPT0WU
K5 MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jFS2lEPTB;MD60O|AzPSEQvF2= NYPUSVB5W0GQR1XS
HOP-62 NEi3fG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwNEizOVgh|ryP MVHTRW5ITVJ?
NCI-H187 MmCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PJTmlEPTB;MD60PVIzPyEQvF2= NHmzfYdUSU6JRWK=
BE-13 MojyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwNEm2OlEh|ryP NGnqN4VUSU6JRWK=
HC-1 NUjNXVZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;ySZpvUUN3ME2wMlUxPDd|IN88US=> MmPPV2FPT0WU
ACN MmTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwNUGwNlgh|ryP NHLJeXNUSU6JRWK=
HCC1599 NHTzU3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TpRmlEPTB;MD61NVU4KM7:TR?= NWXaOXFtW0GQR1XS
MV-4-11 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7mXo5CUUN3ME2wMlU{ODRzIN88US=> NIWxWoRUSU6JRWK=
LC-2-ad MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Tr[WlEPTB;MD61N|Y3OyEQvF2= Mm[1V2FPT0WU
HL-60 NULkV3pnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3GdWxKSzVyPUCuOVQzPjFizszN NW[wVHNnW0GQR1XS
NB17 M3PsbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTBwNUSzPEDPxE1? MoK4V2FPT0WU
TE-1 MmfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PEPWlEPTB;MD61OVMxPiEQvF2= NIDLR|NUSU6JRWK=
NCI-H524 MknOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UUYxKSzVyPUCuOVU1ODFizszN M4HNSHNCVkeHUh?=
MZ7-mel NFi1dmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTBwNU[xNFUh|ryP MULTRW5ITVJ?
L-363 MnjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mne5TWM2OD1yLkW2OlU4KM7:TR?= NI\lOVFUSU6JRWK=
BL-41 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2W4d2lEPTB;MD61Olg5QSEQvF2= M3vDb3NCVkeHUh?=
LU-134-A NFXSVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr2RnRJUUN3ME2wMlU4ODd|IN88US=> MYnTRW5ITVJ?
SIG-M5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwNUe4OFgh|ryP NFmybolUSU6JRWK=
ONS-76 MkLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYPJR|UxRTBwNUiyOFIh|ryP NFntVVJUSU6JRWK=
KARPAS-299 M3fDfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPGTWM2OD1yLkW4OVA1KM7:TR?= M331Z3NCVkeHUh?=
DU-4475 NV;oZ3BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwNUi3NFMh|ryP MXLTRW5ITVJ?
NB69 NGDPO3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwNUm4NlUh|ryP MVLTRW5ITVJ?
MHH-PREB-1 NWjaWmVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwNkC3NVkh|ryP NUPyW5VEW0GQR1XS
LU-165 NEjkOIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PySGlEPTB;MD62NVgyOiEQvF2= NX;tbZUxW0GQR1XS
LOUCY NFOyeXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmixTWM2OD1yLk[zN|Y1KM7:TR?= NG[ydVBUSU6JRWK=
NCI-H526 NEn3NplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3X3cmlEPTB;MD62N|U1OSEQvF2= NHnmT5hUSU6JRWK=
KE-37 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{D4TWlEPTB;MD62OFI4PiEQvF2= NX3U[WVNW0GQR1XS
NALM-6 NH3XSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fjSWlEPTB;MD62OFg3KM7:TR?= MmTZV2FPT0WU
CW-2 NYfNepRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fpZ2lEPTB;MD62OVc6PCEQvF2= NGXtNI9USU6JRWK=
SU-DHL-1 NV3yPHNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvDbnZKSzVyPUCuOlU6PDdizszN NGDUTnZUSU6JRWK=
NB13 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\UTWM2OD1yLk[2PFE4KM7:TR?= M2K2bnNCVkeHUh?=
QIMR-WIL NVnJ[G5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rsRWlEPTB;MD62PFM1OyEQvF2= Ml7tV2FPT0WU
ECC12 M1WyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULqVGZrUUN3ME2wMlcxODh4IN88US=> M{D2W3NCVkeHUh?=
KALS-1 M4HJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKzdYZ5UUN3ME2wMlcxPDl{IN88US=> MWHTRW5ITVJ?
COR-L279 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwN{C5PVYh|ryP M2T6bXNCVkeHUh?=
NB14 M1nqbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHKweo9KSzVyPUCuO|I3OTdizszN NF\QTYFUSU6JRWK=
CCRF-CEM MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnTWGxuUUN3ME2wMlc1PjZzIN88US=> NXPhOpB4W0GQR1XS
SW954 NH2ybZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEn6dpdKSzVyPUCuO|U6QTlizszN NGjwfJpUSU6JRWK=
IST-SL1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwN{ezOFgh|ryP M{X3e3NCVkeHUh?=
LAMA-84 MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwN{e1Olch|ryP MnnHV2FPT0WU
Daudi Mlj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nUTmlEPTB;MD63O|Y5OSEQvF2= NFfLVYFUSU6JRWK=
BC-3 M{LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTLcppKSzVyPUCuO|g{ODhizszN NYL3[Id5W0GQR1XS
HCC2998 M{jNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK0SJZKSzVyPUCuO|g{PiEQvF2= M3PZfHNCVkeHUh?=
NCI-H69 NUHobJRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7xW5RPUUN3ME2wMlgxOTR5IN88US=> NUDqTVRZW0GQR1XS
CPC-N MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\LW5BDUUN3ME2wMlgxPTJ2IN88US=> MlvjV2FPT0WU
NOMO-1 NXT0XoIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzwTWM2OD1yLkixNFg1KM7:TR?= MnTaV2FPT0WU
CESS MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7kdpJwUUN3ME2wMlgyOTl5IN88US=> NU\T[Gt1W0GQR1XS
LC4-1 M3\OTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XKNGlEPTB;MD64OFAxPyEQvF2= MnjqV2FPT0WU
BL-70 MnTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPOTWM2OD1yLki1O|AzKM7:TR?= M2XLVHNCVkeHUh?=
ES4 NIiwT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVT6T4J1UUN3ME2wMlg2QDZ6IN88US=> NXjYRlBJW0GQR1XS
HCE-T MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwOEexO|Eh|ryP NHv2RpFUSU6JRWK=
JAR M{KwWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnr[oVUUUN3ME2wMlg4QDJ5IN88US=> MYPTRW5ITVJ?
ST486 MnfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETiUndKSzVyPUCuPFc6OTdizszN NFv0ZmJUSU6JRWK=
KS-1 MnnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS5RWdKSzVyPUCuPFgxQTZizszN NY\pRXZHW0GQR1XS
GDM-1 NYnOd2RjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\UTWM2OD1yLki4Olg4KM7:TR?= NGT2S3RUSU6JRWK=
EHEB NX[0WpVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\2TWM2OD1yLkmyOVg2KM7:TR?= MnzsV2FPT0WU
LB2518-MEL NF7HbIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGiyeXdKSzVyPUCuPVMzQDRizszN M1Hv[nNCVkeHUh?=
GOTO M13sbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwOUWwO|Yh|ryP M2\QcXNCVkeHUh?=
LXF-289 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwOUW5NFEh|ryP NEHlfWRUSU6JRWK=
ES6 NEXEXZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwOU[0N|ch|ryP M{DvNnNCVkeHUh?=
OS-RC-2 Mn;GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXVWlRKSzVyPUCuPVY5OyEQvF2= M1XEOHNCVkeHUh?=
DMS-153 NWnrfnRST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwOUe0Olkh|ryP NXPa[mdlW0GQR1XS
SK-PN-DW MoX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTBTWM2OD1yLkm3PFMyKM7:TR?= M1LZSHNCVkeHUh?=
HH NUHy[JR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WwbWlEPTB;MD65PFk2QSEQvF2= NVPMVGhpW0GQR1XS
SH-4 NX7MWIJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLpfoU3UUN3ME2xMlAzPDFizszN MV3TRW5ITVJ?
MOLT-4 MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3k[lJvUUN3ME2xMlA{PDV2IN88US=> MlmxV2FPT0WU
TGW MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMEe2O|Uh|ryP MVLTRW5ITVJ?
L-540 NFHkPYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwMUC2NFQh|ryP NGL1b3RUSU6JRWK=
PF-382 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDFcG1KSzVyPUGuNVE2OTNizszN NIHMO4NUSU6JRWK=
LC-1F NVX3ZohXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTsdZFKSzVyPUGuNVIxODdizszN NYn4Z453W0GQR1XS
OVCAR-4 NEPUc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoKyTWM2OD1zLkGzNVY2KM7:TR?= MnfrV2FPT0WU
A4-Fuk NXyxU25IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzCdpFKSzVyPUGuNVU{PjRizszN NWDiZ40xW0GQR1XS
HCC2218 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[4d5BJUUN3ME2xMlE3PjRzIN88US=> M4fTenNCVkeHUh?=
HAL-01 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37QRWlEPTB;MT6xOlk1OyEQvF2= MWrTRW5ITVJ?
IST-MEL1 NVTUOphTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;wcIZKSzVyPUGuNVc3PTlizszN MWDTRW5ITVJ?
NCI-H719 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTFwMUe4PVgh|ryP MmDXV2FPT0WU
EVSA-T NXjzS|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHiTWM2OD1zLkG4NVE1KM7:TR?= NYHsSGdVW0GQR1XS
SK-NEP-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfTRXNKSzVyPUGuNlAzPjZizszN M1TjfHNCVkeHUh?=
OCUB-M NF;lUVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTFwMkG0PFkh|ryP MluzV2FPT0WU
MEG-01 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWxR5dKSzVyPUGuNlIyOThizszN NGTkNJBUSU6JRWK=
no-10 M1fSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPZd4NKSzVyPUGuNlMyOTJizszN M{nvfHNCVkeHUh?=
MHH-CALL-2 NELabXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV74dHJtUUN3ME2xMlI1PzJzIN88US=> NGrtfYhUSU6JRWK=
SK-N-DZ Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DYeGlEPTB;MT6yOFc4PiEQvF2= NWi1UZB4W0GQR1XS
SCLC-21H NUXwSWZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTFwMk[0O|gh|ryP NVjhNppsW0GQR1XS
CTV-1 NWj2U21IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vLeGlEPTB;MT6yO|QzPSEQvF2= NGTTW5VUSU6JRWK=
NB1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\oOlczUUN3ME2xMlI4PzN{IN88US=> MXPTRW5ITVJ?
NCI-H64 NXzQV45kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xn[GlEPTB;MT6yPFQ3OiEQvF2= NH;aXGtUSU6JRWK=
MDA-MB-134-VI Mmr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWC5OHVFUUN3ME2xMlI5PTd5IN88US=> MYjTRW5ITVJ?
LB2241-RCC NIruR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2\KbGlEPTB;MT6yPFY3OyEQvF2= M2G2bXNCVkeHUh?=
8-MG-BA NX;nVm1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHy2fIZKSzVyPUGuNlg5PjZizszN NIHhdmRUSU6JRWK=
LP-1 NVXzXJB7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojXTWM2OD1zLkK5PVQ4KM7:TR?= MXXTRW5ITVJ?
LS-411N Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHR[WJKSzVyPUGuN|A6QThizszN MUDTRW5ITVJ?
CAL-148 M4XObWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2TLWWlEPTB;MT6zNlU1OiEQvF2= NUG4XmdOW0GQR1XS
NCI-H2171 NGj3b2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L6PWlEPTB;MT6zOFUxOiEQvF2= NGHhXm5USU6JRWK=
JiyoyeP-2003 M1XpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwM{WzPUDPxE1? NFXESZNUSU6JRWK=
NCI-H2107 MlXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDkTWM2OD1zLkO1PFg{KM7:TR?= M1fiVHNCVkeHUh?=
BB30-HNC NYH6[HIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXXcHVKSzVyPUGuN|g6PzhizszN NWrlZ5dbW0GQR1XS
K-562 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFwM{myNVkh|ryP NWS3UZlpW0GQR1XS
PSN1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHH1Nm9KSzVyPUGuOFIzQDdizszN NEfRb49USU6JRWK=
HCC2157 MnvwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzETWM2OD1zLkSyOlkyKM7:TR?= MoPqV2FPT0WU
SBC-1 NWPUOYVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPRcnpxUUN3ME2xMlQzPzRzIN88US=> Mn7IV2FPT0WU
MC116 MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTFwNEO2NVUh|ryP M{j2bnNCVkeHUh?=
KARPAS-422 NHL4VZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwNEWzOVgh|ryP MknwV2FPT0WU
LB996-RCC M4nPUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHWSGlKSzVyPUGuOFcyODNizszN NFm1e4NUSU6JRWK=
MSTO-211H NFPPZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mke2TWM2OD1zLkS3PVg4KM7:TR?= MWrTRW5ITVJ?
BT-474 Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nZVWlEPTB;MT61NVc3PCEQvF2= NHvBd2ZUSU6JRWK=
A388 M4L2R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4q1TWlEPTB;MT61NVk1PSEQvF2= NES0S2FUSU6JRWK=
SJSA-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2ny[WlEPTB;MT61NlI3KM7:TR?= NEPvN3pUSU6JRWK=
COLO-829 M3HXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnuTWM2OD1zLkWzOVY1KM7:TR?= Mlu0V2FPT0WU
KM-H2 M4jFVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnSTWM2OD1zLkW2Olch|ryP MXzTRW5ITVJ?
GR-ST MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrmTohKSzVyPUGuOVY5OiEQvF2= NG\rcpVUSU6JRWK=
RPMI-8866 NIDndYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvVTWM2OD1zLk[wNVQ1KM7:TR?= NGTNTXdUSU6JRWK=
KG-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrSTWM2OD1zLk[xPVAyKM7:TR?= MlvvV2FPT0WU
NCI-H82 NUXjS2tyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqS3dKSzVyPUGuOlM1ODZizszN NEW1RWJUSU6JRWK=
LB1047-RCC M3zpSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13mfGlEPTB;MT62N|Q2QSEQvF2= NUTrdZJKW0GQR1XS
KM12 NHPObJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;uTWM2OD1zLk[0O{DPxE1? MXrTRW5ITVJ?
NB5 M1i0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37LbWlEPTB;MT62OVY4PyEQvF2= MluzV2FPT0WU
HDLM-2 NIH3N4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTNWIoxUUN3ME2xMlY5OjhzIN88US=> NY\kb3dQW0GQR1XS
KU812 NXTVeJlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrrVI91UUN3ME2xMlY6PjB3IN88US=> NXPZfmY2W0GQR1XS
DB M3Hzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjvSpltUUN3ME2xMlcxOzV|IN88US=> NVHY[XZDW0GQR1XS
HD-MY-Z MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTFwN{WyN|Qh|ryP Ml\lV2FPT0WU
KURAMOCHI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDGXlFKSzVyPUGuO|czODdizszN M2[2cHNCVkeHUh?=
ETK-1 M33K[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml22TWM2OD1zLke4PFc6KM7:TR?= NH7Wc41USU6JRWK=
SK-UT-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwN{mzPFgh|ryP NFridFdUSU6JRWK=
HUTU-80 M33wVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwN{m1NFgh|ryP NGnKPJZUSU6JRWK=
ES7 NGfJR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTFwOECzNFIh|ryP MVTTRW5ITVJ?
SW872 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LiU2lEPTB;MT64NVM6PSEQvF2= NXW0VJBCW0GQR1XS
TK10 M2LIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P2cGlEPTB;MT64N|ExQCEQvF2= MYDTRW5ITVJ?
LB831-BLC NI\4eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfqTWM2OD1zLkizOVY{KM7:TR?= M4rlSnNCVkeHUh?=
TE-9 NV:zdppmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fpT2lEPTB;MT64OFQzOiEQvF2= NITJe|ZUSU6JRWK=
MLMA MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwOEiyN|Qh|ryP M3jwNXNCVkeHUh?=
D-542MG NHztSmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjqb4VZUUN3ME2xMlg6Ozd|IN88US=> NV\nR3M5W0GQR1XS
EW-16 M376Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHYeY1GUUN3ME2xMlkzPzJizszN MVPTRW5ITVJ?
LOXIMVI M4CwZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7sc5cxUUN3ME2xMlk{OjhizszN Mlr2V2FPT0WU
GB-1 NYXwOVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXtRZZJUUN3ME2xMlk{QDZ4IN88US=> Moe0V2FPT0WU
IST-SL2 NEPOPIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLvTZVKSzVyPUKuNFAzPjJizszN NG\Kd2dUSU6JRWK=
LAN-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTJwMEG5OlYh|ryP NETTb|RUSU6JRWK=
NCI-H510A M1TET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwMES1NFIh|ryP NHvUfVBUSU6JRWK=
NCI-H1092 NHzseW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moq3TWM2OD1{LkC1NVI1KM7:TR?= NWDmU49{W0GQR1XS
HT NUXlfmJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f5Z2lEPTB;Mj6xNFQ2PCEQvF2= M3;MR3NCVkeHUh?=
RL95-2 MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTiXoVKSzVyPUKuNVE1QDJizszN MnvjV2FPT0WU
NCI-H1355 NH7aXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLmeYxKSzVyPUKuNVE4QTJizszN MX3TRW5ITVJ?
NCI-H720 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofGTWM2OD1{LkG2PFc{KM7:TR?= NXHDXWRZW0GQR1XS
NCI-H1522 NHLjbW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnk[YJmUUN3ME2yMlIyPzJ|IN88US=> MlvLV2FPT0WU
LB373-MEL-D M3jDZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LaOWlEPTB;Mj6yOlkxOiEQvF2= M330XXNCVkeHUh?=
DG-75 NF\xWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rmWWlEPTB;Mj6yO|E1QCEQvF2= NV3KXo9CW0GQR1XS
ML-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rpNmlEPTB;Mj6zNlg2PSEQvF2= Mo[zV2FPT0WU
SF126 M{i5T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;yWY1OUUN3ME2yMlM{ODl2IN88US=> M4LGdnNCVkeHUh?=
MPP-89 NX7WOXMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwM{OxOFUh|ryP M4LzSXNCVkeHUh?=
NCI-H345 MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnWSWJvUUN3ME2yMlM{Ojd5IN88US=> MofNV2FPT0WU
LS-123 NILiZYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfaN2FKSzVyPUKuN|Q6OzZizszN M1PBTXNCVkeHUh?=
NB10 M17DRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYmyc|E{UUN3ME2yMlQyODl{IN88US=> M4XtUXNCVkeHUh?=
CGTH-W-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LGWmlEPTB;Mj60NlI3PyEQvF2= MYfTRW5ITVJ?
CP66-MEL NH\Vc2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnUSplKSzVyPUKuOFc4PyEQvF2= M3f1c3NCVkeHUh?=
L-428 NXj3UnJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTINJM{UUN3ME2yMlQ5PTJzIN88US=> NXXYO5FZW0GQR1XS
DMS-79 NITXW5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwNUSxNFMh|ryP NFGzXmlUSU6JRWK=
NCI-H1882 NGjOTG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUe4[|l7UUN3ME2yMlY4PTZ{IN88US=> M2ryTnNCVkeHUh?=
KGN NH7mfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1XVemlEPTB;Mj63Olg4PiEQvF2= Mn;pV2FPT0WU
EW-1 NX2wPW9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XXeWlEPTB;Mj63O|A5OyEQvF2= M33nUXNCVkeHUh?=
U-266 NVrQV4xVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;NPJRGUUN3ME2yMlg1QDJ|IN88US=> M{HSS3NCVkeHUh?=
COLO-320-HSR MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXOb4xKSzVyPUKuPFU3PDFizszN MXrTRW5ITVJ?
KMOE-2 Mk\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HXPGlEPTB;Mj64O|cyOSEQvF2= NEfxUYZUSU6JRWK=
BB49-HNC NIj3WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\ocGlEPTB;Mj65NlQ5KM7:TR?= NFThPIlUSU6JRWK=
GI-1 NX7PRYN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\LTWM2OD1{LkmyPVU4KM7:TR?= NHTneHVUSU6JRWK=
NCI-H1304 NF3sdlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHhUoNKSzVyPUOuNFA2OTFizszN M1rRdnNCVkeHUh?=
NCI-H2227 NWm1cVNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTNwMEKwO|kh|ryP M{Xo[3NCVkeHUh?=
U-87-MG MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jqVWlEPTB;Mz6wN|UyOyEQvF2= NG[5bVJUSU6JRWK=
NCI-H747 MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXs[XpIUUN3ME2zMlA2OjB4IN88US=> NXywb3pqW0GQR1XS
CTB-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH6VmNMUUN3ME2zMlA2Ozd4IN88US=> MUTTRW5ITVJ?
RPMI-8226 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTsWGhzUUN3ME2zMlE1Ozd6IN88US=> MoXGV2FPT0WU
NCI-H2141 MnPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fQUGlEPTB;Mz6xOlU3PiEQvF2= NX\aOoxoW0GQR1XS
IST-MES1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfMTpI3UUN3ME2zMlE5Ojd7IN88US=> MY\TRW5ITVJ?
TE-5 NEK0WFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDZTWM2OD1|LkKxN|QzKM7:TR?= NX7TbmZ6W0GQR1XS
UACC-257 NV73cW1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzpTWM2OD1|LkSzOlU6KM7:TR?= NHXHPWNUSU6JRWK=
SK-N-FI M4f3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTNwNEWyNlch|ryP NXnOO4FFW0GQR1XS
MFH-ino NFvFV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTNwNE[1PFkh|ryP NHzGZYxUSU6JRWK=
SF268 MoHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mki5TWM2OD1|LkS4NVc1KM7:TR?= NIjsNpNUSU6JRWK=
TE-12 NUDUeJg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nXSmlEPTB;Mz61NVY6QSEQvF2= NYD1RohjW0GQR1XS
NB6 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTNwNUW1OlMh|ryP NEi0NpNUSU6JRWK=
DJM-1 NHnLV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHIbFVKSzVyPUOuOVk5QTlizszN NH3mNJFUSU6JRWK=
MZ1-PC Mn\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MornTWM2OD1|Lk[xOlI1KM7:TR?= MmTpV2FPT0WU
OCI-AML2 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\DR4F{UUN3ME2zMlYzPjdzIN88US=> NH3JXGNUSU6JRWK=
NCI-H1155 NHqzVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTNwN{C5OFch|ryP MmnnV2FPT0WU
RKO NUjiS4pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYNm81UUN3ME2zMlc4OTh7IN88US=> MoroV2FPT0WU
ECC4 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;WTWM2OD1|Lkm3NVk2KM7:TR?= MYrTRW5ITVJ?
BB65-RCC MlHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV3VU41LUUN3ME2zMlk4PTR5IN88US=> NGLQNlBUSU6JRWK=
EB-3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1[5R2lEPTB;Mz65PVY{OyEQvF2= NX;PS49jW0GQR1XS
SHP-77 NFHmVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFH3cVlKSzVyPUSuNFA2OjRizszN NIPabmhUSU6JRWK=
NCI-H2196 Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDMS2JbUUN3ME20MlA2PjJ3IN88US=> M1nIb3NCVkeHUh?=
GI-ME-N NHnqVoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHNfXhOUUN3ME20MlA3Ozl7IN88US=> MWXTRW5ITVJ?
MN-60 NEL0SZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLOem52UUN3ME20MlExQDdizszN M{S0bHNCVkeHUh?=
NCI-H1694 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jLXmlEPTB;ND6xN|QxPSEQvF2= NWPXe3ZpW0GQR1XS
LU-65 MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPGSmhKSzVyPUSuNVU{OzJizszN M1TzPXNCVkeHUh?=
NCI-H1436 NXe5OGhOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwMUizN|Mh|ryP MWPTRW5ITVJ?
KINGS-1 NWDy[mV3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3qTWM2OD12LkOxOFMzKM7:TR?= MWDTRW5ITVJ?
GT3TKB MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\KUlNKSzVyPUSuN|MzPjhizszN NVTSWlBvW0GQR1XS
Becker NWLxNHlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwM{ezNVIh|ryP Ml;oV2FPT0WU
HCC1187 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfZTWM2OD12Lki5OlU4KM7:TR?= MUjTRW5ITVJ?
D-502MG M3[0NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvVdHlKSzVyPUWuNFA1OTZizszN NGr5UmxUSU6JRWK=
VA-ES-BJ NFHpcWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnS0TWM2OD13LkGzO|c5KM7:TR?= M2rienNCVkeHUh?=
NB7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4T0Z2lEPTB;NT6xOFEyOiEQvF2= MXLTRW5ITVJ?
SW962 NFPxXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoL5TWM2OD13LkO4PFE1KM7:TR?= M4TuVnNCVkeHUh?=
no-11 NHKwbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfTbmpKSzVyPUWuO|Y{PDNizszN MWHTRW5ITVJ?
KNS-81-FD NEW0[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vkR2lEPTB;NT65NFY6PCEQvF2= M{H6dHNCVkeHUh?=
COLO-684 NEixe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnXe2VKSzVyPUWuPVk1QTRizszN M4T4Z3NCVkeHUh?=
D-263MG M{fwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTZwMEi4PVUh|ryP NIiwWnZUSU6JRWK=
EW-24 NWC0Sph3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTZwMki1NUDPxE1? NYDYOGJlW0GQR1XS
TE-10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi1U45KSzVyPU[uOFI3OjNizszN M4\u[XNCVkeHUh?=
EKVX NInP[GFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHBVoFkUUN3ME22MlQ3OzJzIN88US=> NI\KPJhUSU6JRWK=
NCI-H1648 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZwNke1OVch|ryP NE\vUI1USU6JRWK=
LB771-HNC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XES2lEPTB;Nj65NlMxOSEQvF2= Mki3V2FPT0WU
SK-MEL-1 NUP2TFRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7EOZNKSzVyPUiuNVMyPjZizszN M1;TcXNCVkeHUh?=
COLO-668 M1vhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXOfVRKSzVyPUiuNlc4QDZizszN Ml\WV2FPT0WU
EW-12 M1v5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;BdlBlUUN3ME24MlQxQDB|IN88US=> NIi1fJhUSU6JRWK=
A253 NGPoTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHP[otKSzVyPUiuPFQ3PjFizszN MX;TRW5ITVJ?
NCI-H2126 NH\pS5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTnTWM2OD16Lki5N|E6KM7:TR?= MXHTRW5ITVJ?
Calu-6 NX7xSIhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDxbFlJUUN3ME24Mlk6ODR{IN88US=> NHn3fG9USU6JRWK=
NCI-H23 NHXGZmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XyfmlEPTB;OT6xO|c1PiEQvF2= M3TpdXNCVkeHUh?=
WSU-NHL NFW5SJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD17Lke3OFc5KM7:TR?= MmrKV2FPT0WU
MMAC-SF MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fVSGlEPTB;OT65O|kxPCEQvF2= NEDudJFUSU6JRWK=
SK-LMS-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2XER2lEPTB;MUCuNlg{PCEQvF2= NVPjN4hMW0GQR1XS
GCIY M1XrNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELVWIlKSzVyPUGwMlU6OjRizszN MnrQV2FPT0WU
TE-15 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTGPWFKSzVyPUGxMlYxODRizszN MX3TRW5ITVJ?
EoL-1-cell M1q0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXKTWM2OD1zMT63OlgzKM7:TR?= MW\TRW5ITVJ?
NCI-H2081 M2P4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnvS|BKSzVyPUGxMlc4QDZizszN NFzOTVRUSU6JRWK=
EW-3 M2PQTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3Z[ndsUUN3ME2xNk4zPDZ|IN88US=> MWLTRW5ITVJ?
CAS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTHTWM2OD1zMj6zOlMyKM7:TR?= M3vHPXNCVkeHUh?=
C2BBe1 NFGzWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrSSGhGUUN3ME2xNk43OTNzIN88US=> NYPBO4xFW0GQR1XS
D-247MG M1j2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrPcW1rUUN3ME2xNk44QTV{IN88US=> NYXCXJRIW0GQR1XS
NCI-SNU-5 MkPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTF{LkiwNVMh|ryP M{TndHNCVkeHUh?=
LS-1034 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn[wTWM2OD1zND6zPVc2KM7:TR?= NYLId5BLW0GQR1XS
EW-18 MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j6[WlEPTB;MUSuOFQ5KM7:TR?= M2e5cHNCVkeHUh?=
Raji MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;lVGlEPTB;MUSuOVA1QSEQvF2= MlPiV2FPT0WU
D-283MED M2fVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrsZnJ{UUN3ME2xOE43OjdzIN88US=> M1vTd3NCVkeHUh?=
MZ2-MEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjFZZB[UUN3ME2xOE46Pjl4IN88US=> M{O1cXNCVkeHUh?=
NCI-SNU-16 MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTF3LkS2N|Mh|ryP MnmyV2FPT0WU
P30-OHK M3u0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIr4fFhKSzVyPUG3Mlc5OzFizszN MUHTRW5ITVJ?
RXF393 NHzYdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf2TWM2OD1zOT6wNVg3KM7:TR?= MV\TRW5ITVJ?
NCI-H1395 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvPNFA4UUN3ME2yNE43PzB|IN88US=> M{PvXnNCVkeHUh?=
U-698-M MlnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITnVGhKSzVyPUKwMlcxPzVizszN MkjlV2FPT0WU
NCI-SNU-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\WfXhKSzVyPUKwMlczOjNizszN Mny4V2FPT0WU
SW684 M2rYbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoHnTWM2OD1{MT6xO|E3KM7:TR?= NHjQcnRUSU6JRWK=
NCI-H716 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXCc3RKSzVyPUKxMlMyPTRizszN NV3MSVBXW0GQR1XS
JVM-2 NIq0c3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TwPGlEPTB;MkGuOFE{OyEQvF2= NVHIcIM6W0GQR1XS
NCI-H1581 NHnSS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTJ{LkSxOFgh|ryP M2OxU3NCVkeHUh?=
CA46 M3nFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvVTWM2OD1|MT62PVM3KM7:TR?= MWnTRW5ITVJ?
SNB75 NG\v[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PKc2lEPTB;M{OuOlUxOyEQvF2= NVXyenpZW0GQR1XS
KNS-42 M4XPOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILuZY1KSzVyPUO1Mlk3OjRizszN MXjTRW5ITVJ?
TUR NEHtWIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHhSpBLUUN3ME2zOk4xPTJzIN88US=> MXPTRW5ITVJ?
REH NYno[2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4H4T2lEPTB;M{euPFIyOSEQvF2= Mnn1V2FPT0WU
EW-22 NWHkVY46T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nUR2lEPTB;NEKuNlg5PSEQvF2= NXXGcIhwW0GQR1XS
NCI-H446 NEHvWWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1L2dGlEPTB;NEKuO|g2OyEQvF2= MUPTRW5ITVJ?
ES3 M3XmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnM[4pPUUN3ME20N{4yOzN7IN88US=> MUXTRW5ITVJ?
EW-11 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDzOYJKSzVyPUS0MlgzOThizszN MYjTRW5ITVJ?
RH-1 NUPaUGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7uTWM2OD12Nz61PFEzKM7:TR?= Mn3SV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

Protocol

Kinase Assay:

[6]

+ Expand

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
Cell Research:

[2]

+ Expand
  • Cell lines: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • Concentrations: ~ 10 μM
  • Incubation Time: 3 days
  • Method:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • Formulation: Dissolved with 0.05 N HCl, 0.1% Tween 80
  • Dosages: 12.3, 24.5 and 49 mg/kg
  • Administration: Administered orally once daily 5 days per week for 4 weeks
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 75 mg/mL (199.25 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300 10mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 376.41
Formula

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
Synonyms SNDX-275

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03018249 Not yet recruiting Grade 1 Endometrial Endometrioid Adenocarcinoma|Grade 2 Endometrial Endometrioid Adenocarcinoma|Grade 3 Endometrial Endometrioid Adenocarcinoma|Uterine Corpus Adenosarcoma National Cancer Institute (NCI) August 2017 Phase 2
NCT02697630 Not yet recruiting Metastatic Uveal Melanoma Vastra Gotaland Region|Merck Sharp & Dohme Corp.|Syndax Pharmaceuticals March 2017 Phase 2
NCT02936752 Not yet recruiting Previously Treated Myelodysplastic Syndrome National Cancer Institute (NCI) March 2017 Phase 1
NCT03024437 Not yet recruiting Metastatic Cancer|Renal Cancer Roberto Pili|Indiana University January 2017 Phase 1|Phase 2
NCT02780804 Recruiting Childhood Brain Stem Neoplasm|Childhood Lymphoma|Childhood Solid Neoplasm|Pineal Region Neoplasm|Recurrent Childhood Central Nervous System Neoplasm|Recurrent Childhood Visual Pathway Glioma|Refractory Central Nervous System Neoplasm National Cancer Institute (NCI) December 2016 Phase 1
NCT02922933 Recruiting Volunteers|Healthy Volunteers|Human Volunteers|Normal Volunteers Syndax Pharmaceuticals November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Entinostat (MS-275) | Entinostat (MS-275) supplier | purchase Entinostat (MS-275) | Entinostat (MS-275) cost | Entinostat (MS-275) manufacturer | order Entinostat (MS-275) | Entinostat (MS-275) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID